

Dear Dr Xiu-Xia Song, thank you for your thorough and thoughtful review of our manuscript entitled "Tesevatinib Ameliorates Progression of Polycystic Kidney Disease in Rodent Models of ARPKD" (Manuscript # 33475) We have revised the manuscript according to the "Guidelines and Requirement for Manuscript Revision-Basic Study" and we have addressed all suggested changes in the revised manuscript. All changes in the manuscript have been done with track changes so they are readily seen. We have submitted the following documents as required. All the requested documents have been included with this resubmission including:

- 1 33475-Revised manuscript
- 2 33475-Answering reviewers
- 3 33475-Copyright assignment
- 4 33475-Scientific research process
- 5 33475-Audio core tip
- 6 ~~33475-Institutional review board statement~~ NA there were no human samples
- 7 33475-Institutional animal care and use committee statement
- 8 33475-Animal care and use statement
- 9 33475- Biostatistics statement
- 10 33475-Conflict-of-interest statement
- 11 33475-Data sharing statement
- 12 33475-Google Scholar
- 13 33475-Grant application form(s)

We look forward to you have this study published in the World Journal of Nephrology.

Respectfully

Bill Sweeney